China Approves World’s First Bispecific Antibody for Rabies Passive Immunization

Jinghua Pharmaceutical announced on the evening of October 11 that it has received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The application to conduct a clinical trial for its Ji Desheng Snake Pill, adding the indication of shingles, specifically the liver-gallbladder damp-heat syndrome type, has been approved. The announcement shows that the clinical trial application meets the relevant requirements for drug registration, and the National Medical Products Administration has agreed to allow the clinical trial of Ji Desheng Snake Pill for shingles, the liver-gallbladder damp-heat syndrome type, to proceed on the basis of further improving the clinical trial protocol.

MicuRx Pharmaceuticals has signed an exclusive license agreement and a platform technology collaboration agreement with Switzerland's ClearideBio for the MRX-23 project. The nominal cap on milestone payments for the development, registration, and sales of MRX-23 totals 223 million US dollars, while the cap for all platform collaboration projects, if all options are exercised and all milestones are achieved, totals 750 million US dollars. Under the agreement, an upfront payment of 1 million US dollars is payable as agreed after the agreement takes effect and is non-refundable, and near-term development milestone payments are triggered by the first approval of a clinical trial application for the licensed product. Biwin Storage Technology announced that as of September 30, 2026, it had cumulatively repurchased 1,044,700 shares, accounting for 0.22 percent of total share capital, with a total payment of 222 million yuan. The repurchase plan is expected to involve a total amount of 200 million to 250 million yuan. Sino Medical Sciences Technology's coronary balloon dilatation catheter has received approval from Colombia's INVIMA and obtained a medical device registration certificate. Jiangsu Jindike Biotechnology's trivalent influenza vaccine has obtained a drug registration certificate, but the company expects full-year revenue may fall below 100 million yuan and it will not be able to turn a profit. If it triggers the financial delisting risk warning conditions, the Shanghai Stock Exchange will impose a delisting risk warning on the company's shares.